Candriam Luxembourg S.C.A. trimmed its position in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 26.9% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 2,933 shares of the company’s stock after selling 1,077 shares during the quarter. Candriam Luxembourg S.C.A.’s holdings in Henry Schein were worth $249,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Millennium Management LLC grew its holdings in shares of Henry Schein by 60.6% in the first quarter. Millennium Management LLC now owns 33,082 shares of the company’s stock worth $2,223,000 after purchasing an additional 12,482 shares during the last quarter. Janney Montgomery Scott LLC grew its holdings in shares of Henry Schein by 80.5% in the second quarter. Janney Montgomery Scott LLC now owns 6,699 shares of the company’s stock worth $487,000 after purchasing an additional 2,988 shares during the last quarter. BNP Paribas Arbitrage SA grew its holdings in shares of Henry Schein by 228.1% in the second quarter. BNP Paribas Arbitrage SA now owns 89,941 shares of the company’s stock worth $6,533,000 after purchasing an additional 62,531 shares during the last quarter. Advisor Partners LLC bought a new position in shares of Henry Schein in the second quarter worth about $239,000. Finally, Piedmont Investment Advisors LLC bought a new position in shares of Henry Schein in the second quarter worth about $130,000.
HSIC has been the topic of a number of research analyst reports. Craig Hallum upped their price target on shares of Henry Schein from $83.00 to $96.00 and gave the stock a “buy” rating in a report on Tuesday, August 7th. BidaskClub upgraded shares of Henry Schein from a “buy” rating to a “strong-buy” rating in a report on Thursday, November 1st. Barrington Research upped their price target on shares of Henry Schein from $92.00 to $96.00 and gave the stock an “outperform” rating in a report on Thursday, November 8th. Morgan Stanley upped their price target on shares of Henry Schein from $65.00 to $66.00 and gave the stock an “underweight” rating in a report on Tuesday, October 9th. Finally, Goldman Sachs Group began coverage on shares of Henry Schein in a research note on Saturday, October 20th. They issued a “hold” rating and a $78.00 price objective for the company. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $84.41.
Henry Schein (NASDAQ:HSIC) last released its quarterly earnings data on Tuesday, November 6th. The company reported $1.03 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.01 by $0.02. Henry Schein had a net margin of 3.00% and a return on equity of 20.40%. The company had revenue of $3.28 billion during the quarter, compared to analyst estimates of $3.37 billion. During the same period in the prior year, the firm earned $0.87 earnings per share. The firm’s revenue for the quarter was up 3.8% compared to the same quarter last year. Analysts predict that Henry Schein, Inc. will post 4.12 earnings per share for the current fiscal year.
About Henry Schein
Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, animal health clinics, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
Featured Article: How can investors find ex-dividend dates?
Want to see what other hedge funds are holding HSIC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Henry Schein, Inc. (NASDAQ:HSIC).
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.